MedReleaf is the premium, research-and-development driven, medical cannabis producer in Canada and the only ISO 9001 certified cannabis producer in North America. MedReleaf offers a range of medical cannabis products sourced from around the globe and cultivated in their Ontario facility under the strictest guidelines and care. MedReleaf focuses on quality, safety, uniformity, and reliability, and they do it all to improve the quality of life for their patients. MedReleaf is setting The Medical Grade Standard™, because quality assurance is at the core of every product they produce. Through tireless clinical research in concert with the Canadian medical community, MedReleaf is consistently striving to unlock the immense potential of medical cannabis, and is dedicated to leading the way in the discovery of its medical and therapeutic benefits.
Aequus Pharmaceuticals Inc. is a growing specialty pharmaceutical company focused on developing and commercializing high quality, differentiated products. Aequus’ development stage pipeline includes several products in neurology and psychiatry with a goal of addressing the need for improved medication adherence through enhanced delivery systems. Aequus intends to commercialize its internal programs in Canada alongside its current portfolio of marketed established medicines and will look to form strategic partnerships that would maximize the reach of its product candidates worldwide.
Revive Therapeutics Ltd. is focused on the research, development and commercialization of novel medical and pharmaceutical cannabinoid-based therapies by identifying and investigating potential therapies targeting the endocannabinoid system, such as cannabinoids, that may be repurposed for new indications, be delivered in a different way, combined with existing drugs, or be developed as new chemical entities.
A leading technology company focused on innovative digital delivery of data analysis and scientifically validated assessments for more than 30 years, Multi-Health Systems Inc. (“MHS”) serves clients in corporate, clinical, educational, public safety, government, military, pharmaceutical, and research settings. With offices in North America and partners around the world, MHS is dedicated to improving the lives of individuals and communities through technology. MHS has developed leading products such as the Emotional Quotient Inventory (EQ-i 2.0®), the Conners™ suite of ADHD assessments, and the Level of Service™ suite of assessments. MHS has been named one of Canada’s Best Managed Companies since 2013. The best managed designation is a recognized symbol of excellence for Canadian businesses. Additionally, in 2016, MHS won Canada’s 10 Most Admired Corporate Cultures award in the Growth and Small Cap category.
The Hospital for Sick Children
The Hospital for Sick Children (“SickKids”), affiliated with the University of Toronto, is Canada’s most research-intensive hospital and the largest center dedicated to improving children’s health in the country. As innovators in child health, SickKids improves the health of children by integrating care, research and teaching. With a staff that includes professionals from all disciplines of health care and research, SickKids provides the best in complex and specialized care by creating scientific and clinical advancements, sharing knowledge and expertise, and championing the development of an accessible, comprehensive, and sustainable child health system.
Pear Therapeutics is developing drug/software combination products to address a broad range of severe conditions. The company’s eFormulationTM platform combines pharmaceutical preparations with user-friendly, customizable, and scientifically validated software applications. Pear’s patented approach provides better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payors. While Pear’s proprietary approach has broad clinical application, the company is initially focused on disorders of the brain, many of which impose large societal costs and yet still have limited treatment options.
Ontario Brain Institute
The Ontario Brain Institute is a provincially‐funded, not‐for‐profit research center seeking to maximize the impact of neuroscience and establish Ontario as a world leader in brain research, commercialization and care. Convergent partnerships are created between researchers, clinicians, industry, patients, and their advocates to foster discovery and deliver innovative products and services that improve the lives of those living with brain disorders. The Ontario Brain Institute seeks to develop successful Ontario companies and good jobs, data and knowledge that can be shared with the world, new treatments, and improved patient care.